Wide Ranks

AVXL

Anavex Life Sciences Corp.

9.03

Top Statistics
Market Cap 765 M Forward PE -13.28 Revenue Growth 0.00 %
Current Ratio 12.04 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 138 M Total Cash Per Share 1.64 Total Debt
Total Debt To Equity Current Ratio 12.04 Book Value Per Share 1.53
All Measures
Short Ratio 1365.00 % Message Board Id finmb_13580387 Shares Short Prior Month 17 M
Return On Equity -0.3003 City New York Uuid a192134c-09ce-387b-bb62-3b271f6333ed
Previous Close 9.04 First Trade Date Epoch Utc 1 B Book Value 1.53
Beta 0.6040 Volume 1 M Price To Book 5.90
Last Split Date 1 B Fifty Two Week Low 3.25 Total Cash Per Share 1.64
Shares Short Previous Month Date 1 B Target Median Price 40.45 Max Age 86400
Recommendation Mean 1.33 Sand P52 Week Change 0.3133 Target Mean Price 35.47
Net Income To Common -41528000 Short Percent Of Float 0.2288 Implied Shares Outstanding 84 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 138 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0305 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 9.04 Target Low Price 15.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 6.61 Open 9.10
Free Cashflow -19058068 State NY Dividend Yield 0.00 %
Return On Assets -0.2043 Time Zone Short Name EST Trailing Eps -0.5100
Day Low 8.89 Address1 630 5th Avenue Shares Outstanding 84 M
Price Hint 2 Target High Price 46.00 Website https://www.anavex.com
52 Week Change 0.2524 Average Volume 1 M Forward Eps -0.6300
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 1195.10 %
Last Split Factor 1:4 Regular Market Day High 9.44 Is_sp_500 False
Profit Margins 0.00 % Fifty Two Week High 10.45 Day High 9.44
Shares Short 18 M Regular Market Open 9.10 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.2218
Operating Cashflow -30003000 Currency USD Time Zone Full Name America/New_York
Market Cap 765 M Is_nasdaq_100 False Zip 10111
Quote Type EQUITY Industry Biotechnology Long Name Anavex Life Sciences Corp.
Regular Market Day Low 8.89 Held Percent Institutions 0.3208 Current Price 9.03
Address2 20th Floor Financial Currency USD Current Ratio 12.04
Industry Disp Biotechnology Number Of Analyst Opinions 4 Country United States
Float Shares 82 M Two Hundred Day Average 5.35 Enterprise Value 626 M
Forward PE -13.28 Regular Market Volume 1 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Anavex Life Sciences Corp.

, a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases.

Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.

The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease.

Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer.

The company was incorporated in 2004 and is headquartered in New York, New York.